NO990518L - Langtidsvirkende medikamenter og farmas°ytiske sammensetninger som omfatter disse - Google Patents
Langtidsvirkende medikamenter og farmas°ytiske sammensetninger som omfatter disseInfo
- Publication number
- NO990518L NO990518L NO990518A NO990518A NO990518L NO 990518 L NO990518 L NO 990518L NO 990518 A NO990518 A NO 990518A NO 990518 A NO990518 A NO 990518A NO 990518 L NO990518 L NO 990518L
- Authority
- NO
- Norway
- Prior art keywords
- carboxyl
- radical
- amino
- aryl
- alkyl
- Prior art date
Links
- 239000003509 long acting drug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000000524 functional group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 2
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- VRKCDEWVVXAWCZ-UHFFFAOYSA-N amino(nitro)sulfamic acid Chemical compound [O-][N+](=O)N(N)S(O)(=O)=O VRKCDEWVVXAWCZ-UHFFFAOYSA-N 0.000 abstract 1
- -1 amino, carboxyl Chemical group 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 108010006025 bovine growth hormone Proteins 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229960003712 propranolol Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11902996A IL119029A0 (en) | 1996-08-07 | 1996-08-07 | Long-acting drugs and pharamaceutical compositions comprising them |
| PCT/IL1997/000265 WO1998005361A2 (en) | 1996-08-07 | 1997-08-05 | Long-acting drugs and pharmaceutical compositions comprising them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO990518D0 NO990518D0 (no) | 1999-02-04 |
| NO990518L true NO990518L (no) | 1999-04-06 |
Family
ID=11069166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO990518A NO990518L (no) | 1996-08-07 | 1999-02-04 | Langtidsvirkende medikamenter og farmas°ytiske sammensetninger som omfatter disse |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6504005B1 (pt) |
| EP (1) | EP1019089B1 (pt) |
| JP (1) | JP4416184B2 (pt) |
| KR (1) | KR20000029806A (pt) |
| CN (1) | CN1227501A (pt) |
| AT (1) | ATE308998T1 (pt) |
| AU (1) | AU725468B2 (pt) |
| BR (1) | BR9711045A (pt) |
| CA (1) | CA2261835C (pt) |
| CZ (1) | CZ36999A3 (pt) |
| DE (1) | DE69734607T2 (pt) |
| DK (1) | DK1019089T3 (pt) |
| ES (1) | ES2252787T3 (pt) |
| HU (1) | HUP0000809A2 (pt) |
| IL (3) | IL119029A0 (pt) |
| NO (1) | NO990518L (pt) |
| NZ (1) | NZ333845A (pt) |
| WO (1) | WO1998005361A2 (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL139400A0 (en) * | 2000-11-01 | 2001-11-25 | Yeda Res & Dev | Long-acting cytokine derivatives and pharmaceutical compositions comprising them |
| WO2002047716A2 (en) * | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| WO2003034988A2 (en) * | 2001-10-19 | 2003-05-01 | Idexx Laboratories, Inc. | Injectable compositions for the controlled delivery of pharmacologically active compound |
| US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| BE1015608A6 (fr) * | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
| JP4033382B2 (ja) * | 2002-04-08 | 2008-01-16 | 久光製薬株式会社 | インスリン投与装置 |
| SG153699A1 (en) * | 2003-01-16 | 2009-07-29 | Caprotec Bioanalytics Gmbh | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions |
| DK1620118T3 (da) | 2003-04-08 | 2014-09-29 | Yeda Res & Dev | Reversible pegylerede lægemidler |
| DE602004003577T2 (de) * | 2003-04-17 | 2007-09-20 | Jallal Messadek | Flottierende orale Formulierungen mit kontrollierter Freisetzung von Betain |
| BRPI0413276B8 (pt) * | 2003-08-05 | 2021-05-25 | Novo Nordisk As | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica |
| BE1016128A6 (fr) * | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combinaisons therapeutiques |
| US7282487B2 (en) * | 2004-10-28 | 2007-10-16 | Idexx Laboratories | Method for treating bacterial infections in horses or pigs with tilmicosin |
| WO2006050581A2 (en) * | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
| JP2009506978A (ja) * | 2005-04-27 | 2009-02-19 | メッサデク ジャアル | インスリン類の併用 |
| ES2371361T3 (es) * | 2005-12-28 | 2011-12-30 | Novo Nordisk A/S | Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones. |
| EP2167032B1 (en) | 2007-06-13 | 2019-08-07 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
| EP2910571B1 (en) | 2008-03-18 | 2016-10-05 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| WO2009158668A1 (en) | 2008-06-26 | 2009-12-30 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| US20110171312A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
| WO2010033207A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
| PL2431741T3 (pl) * | 2008-10-21 | 2014-01-31 | Baxalta Inc | Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro) |
| BRPI0919946A2 (pt) * | 2008-10-30 | 2016-02-16 | Novo Nordisk As | tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente |
| WO2010100220A1 (en) | 2009-03-05 | 2010-09-10 | Ascendis Pharma As | Interferon alpha carrier prodrugs |
| WO2011013128A2 (en) | 2009-07-31 | 2011-02-03 | Yeda Research And Development Co. Ltd. | Vectors for delivery of neurotherapeutics to the central nervous system |
| US8754190B2 (en) * | 2010-05-05 | 2014-06-17 | Prolynx Llc | Controlled release from macromolecular conjugates |
| RU2013123515A (ru) | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
| EP2490378B1 (en) | 2011-02-18 | 2014-07-09 | NTT DoCoMo, Inc. | Apparatus and method for determining a control unit using feasibility requests and feasibility responses |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| BR112013030933A2 (pt) | 2011-06-02 | 2018-04-24 | Prolor Biotech Inc | agonistas do receptor de glp-1/glucágon de ação prolongada |
| CN104364260B (zh) | 2012-04-11 | 2017-02-22 | 诺和诺德股份有限公司 | 胰岛素制剂 |
| AU2013273135B2 (en) | 2012-06-04 | 2017-12-07 | Opko Biologics Ltd. | Pegylated OXM variants |
| WO2014009316A1 (en) | 2012-07-09 | 2014-01-16 | Novo Nordisk A/S | Novel use of insulin derivatives |
| US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
| MA49116A (fr) | 2016-12-16 | 2020-03-25 | Novo Nordisk As | Compositions pharmaceutiques contenant de l'insuline |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| WO2020165900A1 (en) | 2019-02-11 | 2020-08-20 | Opko Biologics Ltd. | Long-acting glp-2 analogs |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU906340D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| GB8717446D0 (en) | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
| US6313094B1 (en) * | 1990-12-11 | 2001-11-06 | Japan Energy Corporation | β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors |
| JPH0687887A (ja) * | 1992-08-19 | 1994-03-29 | Upjohn Co:The | ペプチドのエナミン誘導体およびそれをプロドラッグとして含有するペプチド製剤 |
| EP0679658A4 (en) | 1993-06-25 | 1997-06-04 | Kyowa Hakko Kogyo Kk | PEPTIDE WITH ANTAGONIST EFFECT OF ENDOTHELIN. |
| US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| DE4437604A1 (de) | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
| JPH10511340A (ja) | 1995-02-09 | 1998-11-04 | ブリガム アンド ウィメンズ ホスピタル | ゲル生成ポリペプチド誘導体 |
| AU5377296A (en) * | 1995-03-30 | 1996-10-16 | Southpac Trust International, Inc. | Self-erecting container which is collapsible to be substanti ally flat |
| US5688992A (en) * | 1995-03-31 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof |
| US5846934A (en) * | 1996-02-20 | 1998-12-08 | American Cyanamid Company | Pure somatostatin antagonist and methods of use thereof |
| US6057297A (en) * | 1996-08-06 | 2000-05-02 | Polifarma S.P.A. | Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof |
-
1996
- 1996-08-07 IL IL11902996A patent/IL119029A0/xx unknown
-
1997
- 1997-08-05 US US09/242,026 patent/US6504005B1/en not_active Expired - Lifetime
- 1997-08-05 ES ES97933828T patent/ES2252787T3/es not_active Expired - Lifetime
- 1997-08-05 AT AT97933828T patent/ATE308998T1/de active
- 1997-08-05 HU HU0000809A patent/HUP0000809A2/hu unknown
- 1997-08-05 BR BR9711045A patent/BR9711045A/pt not_active IP Right Cessation
- 1997-08-05 CN CN97197122A patent/CN1227501A/zh active Pending
- 1997-08-05 KR KR1019997000941A patent/KR20000029806A/ko not_active Application Discontinuation
- 1997-08-05 AU AU37060/97A patent/AU725468B2/en not_active Ceased
- 1997-08-05 DE DE69734607T patent/DE69734607T2/de not_active Expired - Lifetime
- 1997-08-05 NZ NZ333845A patent/NZ333845A/xx unknown
- 1997-08-05 DK DK97933828T patent/DK1019089T3/da active
- 1997-08-05 EP EP97933828A patent/EP1019089B1/en not_active Expired - Lifetime
- 1997-08-05 CZ CZ99369A patent/CZ36999A3/cs unknown
- 1997-08-05 CA CA002261835A patent/CA2261835C/en not_active Expired - Lifetime
- 1997-08-05 WO PCT/IL1997/000265 patent/WO1998005361A2/en active IP Right Grant
- 1997-08-05 IL IL12827497A patent/IL128274A0/xx active IP Right Grant
- 1997-08-05 JP JP50777098A patent/JP4416184B2/ja not_active Expired - Lifetime
-
1999
- 1999-01-28 IL IL128274A patent/IL128274A/en not_active IP Right Cessation
- 1999-02-04 NO NO990518A patent/NO990518L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000029806A (ko) | 2000-05-25 |
| CA2261835A1 (en) | 1998-02-12 |
| NO990518D0 (no) | 1999-02-04 |
| JP2000515542A (ja) | 2000-11-21 |
| DE69734607T2 (de) | 2006-08-03 |
| EP1019089B1 (en) | 2005-11-09 |
| WO1998005361A2 (en) | 1998-02-12 |
| CZ36999A3 (cs) | 1999-07-14 |
| NZ333845A (en) | 2000-09-29 |
| ES2252787T3 (es) | 2006-05-16 |
| WO1998005361A3 (en) | 1998-06-18 |
| DE69734607D1 (de) | 2005-12-15 |
| US6504005B1 (en) | 2003-01-07 |
| EP1019089A2 (en) | 2000-07-19 |
| IL128274A0 (en) | 1999-11-30 |
| JP4416184B2 (ja) | 2010-02-17 |
| HUP0000809A2 (hu) | 2000-11-28 |
| CN1227501A (zh) | 1999-09-01 |
| IL119029A0 (en) | 1996-11-14 |
| IL128274A (en) | 2006-08-01 |
| DK1019089T3 (da) | 2006-03-13 |
| BR9711045A (pt) | 1999-08-17 |
| AU725468B2 (en) | 2000-10-12 |
| ATE308998T1 (de) | 2005-11-15 |
| CA2261835C (en) | 2008-07-29 |
| AU3706097A (en) | 1998-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO990518L (no) | Langtidsvirkende medikamenter og farmas°ytiske sammensetninger som omfatter disse | |
| HUP9903766A2 (en) | Pyridyl alkene- and pyridyl alkine- acid amides, use of them as cytostatics and immunosuppressives, process for their preparation and pharmaceuticals containing the same | |
| DK0623347T3 (da) | Anvendelse af bisphosphonsyrederivater til fremstilling af et lægemiddel til fremme af knogleheling | |
| ATE33838T1 (de) | Thiazolidinderivate, ihre herstellung und diese enthaltende zusammensetzungen. | |
| TR200003632T2 (tr) | Benzotiyepin-1,1-dioksid türevleri, üretim yöntemi, bunları içeren ilaçlar. | |
| MY132385A (en) | 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives | |
| HUP0203184A2 (hu) | Izoxazolkarboxamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0302038A2 (hu) | Biguanidszármazékok alkalmazása hegesedést elżsegítż gyógyszerek elżállítására | |
| YU50302A (sh) | Nova heterociklična jedinjenja, njihove soli i njihova primena u medicini | |
| HUP9702509A2 (hu) | Kondenzált heterociklusos vegyületek aminocsoportjukon szubsztituált származékai, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0001164A2 (hu) | PF1022-ciklodepszipeptid-származékok | |
| NO172233C (no) | Analogifremgangsmaate for fremstilling av anti-aterosklerotisk aktive diarylforbindelser | |
| ES8504737A1 (es) | Procedimiento para la obtencion de nuevos derivados de mercaptoimidazol | |
| HUP0100102A2 (hu) | Fenil-amino-alkilkarbonsav-származékok és fenil-amino-alkilkarbonsav-származékokat tartalmazó gyógyszerészeti készítmények | |
| HUP0202379A2 (hu) | Új vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP9900668A2 (hu) | Szulfamidsavszármazékok, N-acil-szulfonamidok és szulfonil-karbamát-származékok alkalmazása lipoproteinszintet csökkentő gyógyászati készítmények előállítására | |
| DE60017194D1 (de) | Verfahren zur herstellung von carbapenem-antibiotika zubereitungen | |
| HUP0000934A1 (hu) | 4-{2-[N-(3-Fenoxi-2-hidroxi)-propil-amino]-etil}-anilid-származékok és az ezeket tartalmazó gyógyászati készítmények | |
| ATE22284T1 (de) | 2-aminomethyl-6-sulfamoylphenolderivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen. | |
| DE59305351D1 (de) | Neue acyclische amidingruppen-haltige diphosphonsäurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel | |
| BR0317409A (pt) | Compostos cicloalquileno amida 2-piridila e 2-pirimidila, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos | |
| DE60326731D1 (de) | Arzneizubereitung und deren anwendung zur behandlu | |
| RU99105128A (ru) | Лекарственные средства с длительным сроком действия и содержащие их композиции | |
| HUP9801985A2 (hu) | Cisztinszármazékok alkalmazása restenózis gyógyítására használható gyógyszerkészítmények előállítására | |
| DK0693075T3 (da) | Fremgangsmåde til fremstilling af N-phosphono-methylglycinonitril eller derivater deraf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |